Balloul J M, Acres R B, Geist M, Dott K, Stefani L, Schmitt D, Drillien R, Spehner D, McKenzie I, Xing P X
INSERM U74, Université Louis Pasteur, Strasbourg, France.
Cell Mol Biol (Noisy-le-grand). 1994;40 Suppl 1:49-59.
Breast cancer is considered as the major cause of mortality by cancer for women. Even if chemotherapy, radiotherapy and surgery have improved the life expectancy of patients bearing tumours, breast cancer is responsible for the death of 42,000 women per year in USA and 25,000 women in France. In this context, cancer vaccines may add an attractive alternative therapeutic strategy to the current existing treatments. We describe here the construction of recombinant vaccinia viruses co-expressing a tumour associated antigen (MUC 1) and an "adjuvant" cytokine, which have potential applications in the active immunotherapy of breast cancer. Indeed, recombinant vaccinia viruses have been extensively used during the past decade to induce a protective response against a whole variety of pathogens, and has proven to be of great value in the elicitation of a cellular immune response leading to the rejection of tumour grafts in mouse models.
乳腺癌被认为是女性癌症死亡的主要原因。即使化疗、放疗和手术提高了患肿瘤患者的预期寿命，但在美国每年仍有42000名女性因乳腺癌死亡，在法国这一数字为25000名。在此背景下，癌症疫苗可能为现有治疗方法增添一种有吸引力的替代治疗策略。我们在此描述了共表达肿瘤相关抗原（MUC 1）和“佐剂”细胞因子的重组痘苗病毒的构建，其在乳腺癌的主动免疫治疗中具有潜在应用。事实上，在过去十年中，重组痘苗病毒已被广泛用于诱导针对各种病原体的保护性反应，并且已证明在引发细胞免疫反应以导致小鼠模型中的肿瘤移植物排斥方面具有巨大价值。
